Reproducibility of Brain MRI

Reproducibility of Results Clinical Trial

— DANA0  

Official title:

Danish Anaesthesia Study (DANA) 0: Reproducibility of Structural and Functional Magnetic Resonance Imaging of the Brain in Healthy Volunteers - a Pilot Study. First Substudy of the Protocol, 'Neuroplasticity Induced by General Anaesthesia'

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03876236
• Other study ID #: H-18020364
• Status: Completed
• Start date: February 4, 2019
• Est. completion date: May 4, 2019

Study information

• Verified date: March 2021
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to assess the reproducibility over time of functional and structural magnetic resonance imaging, as well as specific biomarkers in plasma in healthy volunteers before and after a two-hour rest. This design mimics the timing of repeated scans and blood sampling before and after two hours of anaesthesia in subsequent substudies of the protocol, 'Neuroplasticity Induced by General Anaesthesia'.

Description:

In the study 'Neuroplasticity Induced by General Anaesthesia', the investigators intend to explore the effects of general anaesthesia on the brain by state-of-the-art magnetic resonance imaging (MRI). MRI data - especially changes in functional MRI recordings - may theoretically depend on a variety of physiological variables such as cerebral blood flow, cerebral blood volume, and cerebral metabolic oxidative rate of oxygen, and may thus also be affected by pharmacological agents. However, to interpret data it is important to know the inherent variability of the scans. This first substudy therefore aims to determine the reproducibility of the MRI recordings without administration of pharmacological agents. Another aim of the study is to ensure feasibility of the design before embarking on the more resource-demanding substudies in anaesthetised subjects. In this substudy, the investigators will perform the same MRI measurements as in the main study; rather than undergoing two hours of general anaesthesia, the volunteers will be subjected to two hours of undisturbed rest. Each participant goes through a pre-study interview and physical examination to ensure that the participant is healthy and suitable for participation. For each participant, the study consists of three study days: Day 0: Baseline MRI and blood tests. Intervention. Two hours of post-intervention care followed by post-intervention MRI and blood tests. Day +1 (the day after Day 0): MRI and blood tests. Day +7 (one week after Day 0): MRI and blood tests. All MRI scans will be performed with a 3 Tesla Philips Achieva d-stream with a 32-channel receive head coil. Blood tests: Haemoglobin, sodium, potassium, white blood count, C-reactive protein (CRP), S calcium-binding protein 100b (S100b), neuron-specific enolase (NSE), interleukin-1 (IL-1), IL-6, IL-8, IL-10, IL-18, tumor necrosis factor Alpha (TNF-Alpha) and transforming growth factor beta (TGF-beta).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: May 4, 2019
• Est. primary completion date: May 4, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Age =18 =35
• Healthy individual
• Normal electrocardiogram (ECG)
• Normal physical examination, including neurological examination, auscultation of the heart and lungs, and measurement of blood pressure and pulse.
• Speaks and understands Danish
• Provides oral and written informed consent
• Right-handed
• American Society of Anaesthesiologists (ASA) class 1 (2)
• Mallampati I-II and simplified airway risk index (SARI) 0-2 (i.e. no indication of difficult intubation. See Appendix for details)
• BMI =18 kg/m2 and =30kg/m2
• Female participants must use safe contraceptives.

Exclusion Criteria:

• Cannot cooperate to tests
• Left-handedness or ambidexterity
• History of cancer, immune disease, autoimmune disease, chronic pain, neurological / psychiatric illness or other serious illness
• Pregnancy
• Weakly intake of >21 (males) or >14 (females) units of alcohol
• Substance abuse (assessed by the investigator)
• Daily use of any medication (contraceptives allowed)
• Consumed anti-depressants during the last 30 days before study days
• Heavy intake of caffeine (> 5 cups/day)
• Smoking during the last 30 days before study days
• Reflux or dyspepsia
• Poor dental status or oral health
• Contraindication to MRI
• Allergy to any kind of medication or material to which the volunteer could be exposed to during this study
• Family history of malignant hyperthermia
• Declines receiving information regarding incidental pathological findings during MRI scans of the brain.
• Otherwise judged unfit for participation by the investigator
• Major trauma or head trauma with any symptoms present at the time of inclusion
• Surgery less than six weeks prior to the study period
• Infection (with fever) less than two weeks prior to the study period
• Expected or suspected difficult airway
• History of complications to general anaesthesia
• Known incident of malignant hyperthermia or unexplained complications to general anaesthesia among close relatives.

Exclusion criteria during the study (leading to withdrawal):

• Any of the above-mentioned exclusion criteria
• Consumption of more than 3 units of alcohol within 24 hours before each study day (intervention day or MRI scan day)
• Consumed analgesics within 3 days before each study day
• Consumed anti-histamines less than 48 hours before each study day
• Intake of caffeine 12 h prior to each study day
• Smoking
• Major trauma or head trauma during the study period
• Surgery less during the study period
• Fever due to any infection < 14 days before the study or during the study

Related Conditions & MeSH terms

• Reproducibility of Results

Locations

Country	Name	City	State
Denmark	Department of Neuroanaesthesiology	Glostrup	Capital Region
Denmark	Functional Imaging Unit, Department for Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet Glostrup	Glostrup	Capital Region

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility and reproducibility: rates of protocol violation and delays as well as adverse events	Evaluation of feasibility of study set-up, as measured by rates of protocol violation and delays as well as adverse events. The time frame mentioned below runs from the first study day, NOT from eligibility interview.	8 days